EMBASE Classic Makes Inroads into Pharmaceutical Industry
Elsevier Signs Agreement with Bayer HealthCare AG
Amsterdam, November 6, 2007 – Elsevier announced today that major global healthcare company, Bayer HealthCare AG, headquartered in Leverkusen, Germany, has signed an agreement to purchase EMBASE Classic. Available in electronic format for the first time, EMBASE Classic is a fully digitized bibliographic database drawn from 43 Excerpta Medica Abstract Journals published between 1947 and 1973. Covering approximately 3,400 international journals, EMBASE Classic indexes more than 1.8 million records from the biomedical and pharmacological literature.
For Bayer HealthCare and other healthcare and biopharmaceutical companies already licensing EMBASE (covering the literature published from 1974-present) or accessing the file via one of the online vendors, EMBASE Classic allows effective and efficient searching of a single file, from 1947 until today. An important benefit of the addition of EMBASE Classic to EMBASE is the documentation of toxicities and adverse effects that have been published about drugs or endogenous compounds at the time. These drugs may be revisited today or serve as controls because of their known adverse effects or specific effects in animals. In addition results of clinical trials published prior to 1974 can now be more easily factored into evidence-based medical assessments.
Edith Bomers, Project Manager, EMBASE Classic, commented that, “We are extremely pleased that the value of EMBASE Classic has already been recognized by Bayer HealthCare AG, one of the world’s leading healthcare companies. EMBASE Classic makes critical biomedical research from the 1950s and 1960s searchable and easily accessible, facilitating much more effective literature searches. In essence it allows revisiting the past to explore the future.”
EMBASE Classic contains historic index terms and has been enhanced with additional indexing controlled by the current version of EMTREE to allow for precision retrieval. EMTREE has furthermore been enhanced with historic index terms. For example, the pre-penicillin era drugs oxophenarsine (tradename mapharsen) to treat syphilis and thiazosulfone (tradename promizole) to treat leprosy and tuberculosis have become EMTREE terms.
EMBASE Classic may be acquired directly from Elsevier or from vendors Ovid, Dialog or DataStar. To celebrate the release of EMBASE Classic, an introductory sales offer is currently available.
Contact Magdaleine Margaritis at email@example.com for additional information and visit www.info.embaseclassic.com to obtain the complete list of Excerpta Medica Abstract Journal titles/years covered.
# # #
EMBASE is a biomedical and pharmacological database that provides access to the most up-to-date information about medical and drug-related subjects. Updated weekly, it contains over 11 million records from 1974 to present, with 600,000+ citations and abstracts added annually. Each record contains the full bibliographic citation, indexing terms and codes; 70% of all citations in EMBASE include author-written abstracts. The EMBASE journal collection is international with over 5,000 biomedical journals from 70 countries. EMBASE features comprehensive coverage of Drug Research, Pharmacology, Pharmacy, Pharmacoeconomics, Pharmaceutics and Toxicology; Human Medicine (Clinical and Experimental); Basic Biological Research; Health Policy and Management; Public, Occupational and Environmental Health; Substance Dependence and Abuse; Psychiatry; Forensic Science; and Biomedical Engineering and Instrumentation.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact:
+31 20 485 3091